Sitemap
- Mixed news
- 12: BioPorto’s NGAL cutoff patent is issued in India
- 11: interim report Q1 2011
- 10: BioPorto’s NGAL cutoff patent is issued in Japan
- 09: Share capital and votes
- 08: Insider’s dealings
- 07: Issue of warrants in BioPorto A/S
- 06: Increase of share capital following exercise of warrants and conversion of bonds
- 05: Development of Annual General Meeting
- 04: Annual General Meeting
- 03: Annual Report 2010
- 02: BioPorto sells NGAL license to major diagnostic company
- 01: BioPorto launches The NGAL Test™ for diagnostic use
- 15: Financial Calendar for 2011
- 14: Prospekt
- 13: Q3 interim report
- 12: Dako brings BioPorto’s kidney injury test to the world market
- 11: BioPorto pre-launches pioneering kidney injury test
- 10: BioPorto completes the subscription of convertible bonds
- 09: Subscription and issue of convertible bonds
- 08: Interim Financial Report for Q2 2010
- 07: BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
- 06: BioPorto’s patent rights for NGAL - opposition to the European patent
- Newsletter July 2010
- 05: Interim financial report Q1
- 04: Development of Annual General Meeting
- 03: Insider's dealings
- 02: Annual General Meeting
- 01: Annual Report 2009
- Newsletter January 2010
- 29: Financial calendar 2010
- 28: Interim financial report for Q3 2009
- 27: Share Capital and Votes
- 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
- 25: Company articles
- 24: BioPorto completes cash issue
- 23: CCH drops lawsuit
- 22: Cash issue, private placement
- 21: Interim Financial Report for Q2 2009
- Documentation: EPO's reply to 3rd party
- 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
- 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
- 18: Objections from CCH against the resumption of grant proceedings
- 17: Insider's dealings
- 16: Insider's dealings
- 15: Insider's dealings
- 14: Interim financial report for Q1
- 13: Change of date for resumption
- 12: Resumption of proceedings for BioPorto's patent
- 11: Issue of warrants in BioPorto A/S
- 10: Insider's dealings
- 09: Development of annual general meeting
- 08: Insider's dealings
- 07: Insider's dealings
- 06: Insider's dealings
- 05: Insider's dealings
- 04: Annual General Meeting
- 03: Launch of APC-PCI ELISA Kit
- 02: Annual Report 2008
- 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed
- Products
- Bioporto Diagnostics
- Antibodyshop
- Alphabetical list
- Cell biology
- Coagulation
- Collectins and related products
- Complement
- Complement component C1-inhibitor (C1INH)
- Complement component C1s (human, pro- and activated enzyme)
- Complement component C2 (human)
- Complement component C3
- Complement component C4 (human)
- Complement component C5 (human)
- Complement component C5b-9 (human)
- Anti-Complement component C5a/C5a(desArg)
- Complement component C9 (human)
- Complement factor B
- Complement factor D (human)
- Complement factor H
- Complement factor I (human)
- Mannan-binding lectin
- Properdin
- Cytokines and hormones
- Adrenomedullin (human)
- alpha-calcitonin gene-related peptide (alpha-CGRP)
- Estrogens
- Exendin-4
- Gastric inhibitory polypeptide (GIP)
- Ghrelin (human, rat)
- Glucagon (human, pig, rat)
- Glucagon-like peptide-1 (GLP-1)
- Glucagon-like peptide-2 (human, hGLP-2)
- Leptin
- Neuropeptide Y
- Pancreatic Polypeptide (human, PP)
- Peptide histidine-methionine (PHM)
- Peptide YY (human, PYY)
- Tumor necrosis factor alpha (TNF alpha)
- Vasoactive intestinal peptide (VIP)
- Enzymes
- Marker molecules
- Acetylcholinesterase
- alpha-fetoprotein (human)
- Amyloid ß-peptide
- Butyrylcholinesterase (human)
- NGAL (dog, neutrophil gelatinase-associated lipocalin)
- NGAL (human, neutrophil gelatinase-associated lipocalin)
- NGAL (monkey, neutrophil gelatinase-associated lipocalin)
- NGAL (mouse, neutrophil gelatinase-associated lipocalin)
- NGAL (pig, neutrophil gelatinase-associated lipocalin)
- NGAL (rat, neutrophil gelatinase-associated lipocalin)
- Placental protein 14 (human, glycodelin A)
- Pregnancy associated plasma protein A (PAPP-A)
- Procollagen
- Microbiology
- Miscellaneous
- Oncology
- Other blood proteins
- Sera and Antigens
- Investors
- Announcements
- 2013
- 15: Development of Annual General Meeting
- 14: Changes to the board of directors
- 13: Annual General Meeting
- 12: Resignation from the board
- 11: Annual report 2012
- 10: Publication of the annual report for 2012 postponed
- 09: BioPorto’s NGAL Test reagent registered for diagnostic use in Brazil – status on progress in the BRIC countries
- 08: Availability of BioPorto’s The NGAL TestTM for Siemens ADVIA® systems
- 07: Development of Extraordinary General Meeting and changes in the composition of the board of directors
- 06: Nomination of candidates for the board of directors
- 05: Announcement from major shareholder regarding the EGM on February 26, 2013
- 04:Resignation from the board
- 03: Notice to Convene Extraordinary General Meeting
- 02: Request for extraordinary General Meeting
- 01: Siemens Diagnostics’ sales activities for NGAL suspended until further
- 2012
- 31: Share Capital and Votes
- 30: Financial calendar 2013
- 29: BioPorto’s NGAL cutoff patent is issued in China
- 28: New shares admitted to trading, the company’s financial situation restored
- 27: BioPorto completes cash issue, private placement
- 26: BioPorto’s The NGAL Test ™ registered for diagnostic use in Russia – status on progress in the BRIC countries
- 25: Increase of the share capital through a cash issue, private placement
- 24: Annoucement from major shareholder
- 23: BioPorto enters agreement on sales cooperation with Siemens
- 22: Interim financial report for Q3
- 21: Cash issue, private placement cancelled, the company in an economically critical state
- 20: Decision on cash issue, private placement postponed to November 2, 2012
- 19: Cash issue, private placement delayed
- 18: BioPorto’s patent rights for NGAL - opposition to the European trauma patent
- 17: Cash issue, private placement to be carried out
- 16: Insider's dealings
- 15: Increase of the share capital through a cash issue, private placement
- 14: Interim report for Q2 2012
- 13: Ruling on NGAL patent appealed to the Supreme Court
- 12: BioPorto obtains its first NGAL patent in the US
- 11:BioPorto wins lawsuit filed against Phadia
- 10: BioPorto enters into an agreement with Wiener Lab Group – Status for the distribution of The NGAL Test
- 09: Interim report Q1 2012
- 08: BioPorto’s NGAL cut-off patent: assessment of the decision in the opposition case
- 07: BioPorto’s NGAL cut-off patent: written decision in the opposition case
- 06: Development of Annual General Meeting
- 05: Annual General Meeting
- 04: The NGAL test registered for diagnostic use in China
- 03: Annual report 2011
- 02: BioPorto’s NGAL cut-off patent rejected following a decision in the opposition case
- 01: Announcement from major shareholder
- 2011
- 23: Amendments for the Interim Financial Report for Q3 2011 for the BioPorto Group
- 22: Financial calendar 2012
- 21: CCH’s European NGAL urine patent revoked after a decision in the opposition case
- 20: Interim Financial Report for Q3 2011 for the BioPorto Group
- 19: Withdrawal of the medicine Xigris from the market
- 18: Issuance of BioPorto’s APC-PCI patent in the US
- 17: Share Capital and Votes
- 16: Increase of the share capital through a cash issue, private placement
- 15: BioPorto’s NGAL cut-off patent, status of opposition case in EU
- 14: Interim Report for Q2 2011 for the BioPorto Group
- 13: FDA accepts The NGAL Test™ for review
- 12: BioPorto’s NGAL cutoff patent is issued in India
- 11: Interim report Q1 2011
- 10: BioPorto’s NGAL cutoff patent is issued in Japan
- 09: Share capital and votes
- 08: Insider’s dealings
- 07: Issue of warrants in BioPorto A/S
- 06: Increase of share capital following exercise of warrants and conversion of bonds
- 05:Development of Annual General Meeting
- 04: Annual General Meeting
- 03: Annual report 2010
- 02: BioPorto sells NGAL license to major diagnostic company
- 01: BioPorto launches The NGAL Test™ for diagnostic use
- 2010
- 15: Financial Calendar 2011
- 14: Prospekt
- 13: Q3 interim report
- 12: Dako brings BioPorto’s kidney injury test to the world market
- 11: BioPorto pre-launches pioneering kidney injury test
- 10: BioPorto completes the subscription of convertible bonds
- 09: Subscription and issue of convertible bonds
- 08: Interim Financial Report for Q2 2010
- 07: BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
- 06: BioPorto’s patent rights for NGAL - opposition to the European patent
- 05: Interim financial report Q1
- 04: Development of Annual General Meeting
- 03: Insider's dealings
- 02: Annual General Meeting
- 01: Annual Report 2009
- 2009
- 29: Financial calendar 2010
- 28: Interim financial statement Q3 2009
- 27: Share Capital and Votes
- 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
- 25: Company articles
- 24: BioPorto completes cash issue
- 23: CCH drops lawsuit
- 22: Cash issue, private placement
- 21: Interim Financial Report for Q2 2009
- 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
- 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
- 18: Objections from CCH against the resumption of grant proceedings
- 17: Insider's dealings
- 16: Insider's dealings
- 15: Insider's dealings
- 14: Interim financial report for Q1
- 13: Change of date for resumption
- 12: Resumption of proceedings for BioPorto's patent
- 11: Issue of warrants in BioPorto A/S
- 10: Insider's dealings
- 09: Development of annual general meeting
- 08: Insider's dealings
- 07: Insider's dealings
- 06: Insider's dealings
- 05: Insider's dealings
- 04: Annual General Meeting
- 03: Launch of APC-PCI ELISA Kit
- 02: Annual Report 2008
- 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed
- 2008
- 25: Insider's dealings
- 24: Insider’s dealings
- 23: BioPorto’s patent rights strengthened for NGAL
- 22: BioPortos patentrettigheder for NGAL
- 21: Financial calendar 2009
- 20: Insider's dealings
- 19: Interim Financial Report for Q3
- 18: Announcement from major shareholder
- 17: Announcement from major shareholder
- 16: Shares and votes
- 15: Insider's dealings
- 14: Insider's dealings
- 13: Announcement from major shareholder
- 12: Interim Financial Report for Q2 2008
- 11: BioPorto’s NGAL patent approved for issue in Europe
- 10: BioPorto launches Rat NGAL ELISA Kit
- 09: New diagnostic application of the APC-PCI test
- 08: Articles of association
- 07: Interim financial statement, first quarter 2008
- 06: Issue of warrants in BioPorto A/S
- 05: Devl. of Annual General Meeting
- 04: Annual General Meeting
- 03: Annual Report 2007
- 02: Financial calendar
- 01: Name change in affiliate
- 2007
- 29: Settlement between SSI and BioPorto
- 28: Insider's dealings
- 27: Interim financial statement
- 26: Devl. of extraordinary general meeting
- 25: Insider's dealings
- 24: Stock capital and votes
- 23: Extraordinary general meeting
- 22: Articles of association
- 21: Exercise of warrants
- 20: Prospectus
- 19: Prospectus Announcement
- 18: Stock capital and votes
- 17: BioPorto continues negotiations
- 16: Insider's dealings
- 15: Devl. of annual general meeting
- 14: Notification from major shareholder
- 13: BioPorto to issue new shares in a directs placement
- 12: Annual general meeting
- 11: Insider's dealings
- 10: Insider's dealings
- 09: Annual report
- 08: Status: NGAL patent
- 07: Devl. of extraordinary general meeting
- 06: Extraordinary general meeting
- 05: Financial calendar 2007 (corrected)
- 04: Fondsrådets afgørelser mv.
- 03: Akkvistition af Merlin
- 02: Alternativ indregning af cellelinier
- 01: Financial Calendar 2007
- 2006
- 22: Status: Akkvisitioner og fokusområder
- 21: Kontant rettet emission – T.DKK 20.000
- 20: NGAL hurtig analyse lancering
- 19: Fondsrådets 2. afgørelse, fuld længde
- 18: Fondsrådets 2. afgørelse
- 17: Korrigerende info til delårsrapport 2006
- 16: Korrigerende info til årsrapport 2004 og 2005
- 15: Fondsrådets afgørelse
- 14: Halvårsrapport 2006
- 13: Fondsrådets regnskabskontrol
- 12: Interface Biotech forhandling
- 11: Akkvisition Merlin Diagnostika
- 10: Warrantsprogram og kapitalforhøjelser
- 09: Insideres handler
- 08: Forløb af ordinær generalforsamling
- 07: Indkaldelse til ordinær generalforsamling
- 06: Årsrapport 2005
- 05: Insideres handler
- 04: Akkvisition af Merlin
- 03: Insideres handel
- 02: Finanskalender 2006
- 01: Akkvisitionsstatus
- 2005
- 2004
- 2013
- Presentations
- Key Figures
- Financial Calendar 2013
- Analyst coverage
- Company Documents
- News mail
- Contact investor relations
- Announcements
